PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines May 27, 2026 08:00AM
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus May 13, 2026 10:11AM
PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus May 13, 2026 08:50AM
PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness Apr 21, 2026 08:00AM
PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides Apr 20, 2026 08:00AM


Apr 16, 2026 08:00AM PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery
Apr 13, 2026 08:00AM PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology
Mar 26, 2026 08:00AM PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches
Mar 3, 2026 08:00AM PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market
Feb 2, 2026 09:27AM PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success
Jan 14, 2026 08:00AM PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
Jan 2, 2026 08:00AM PharmaTher CEO Publishes Letter to Shareholders
Dec 2, 2025 09:53AM PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise
Nov 17, 2025 08:00AM PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program
Oct 17, 2025 08:26AM PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale
Oct 16, 2025 08:04AM PharmaTher prepares FDA package for ketamine Phase 3 Parkinson's study
Oct 16, 2025 08:00AM PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease
Oct 15, 2025 08:00AM PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings
Oct 8, 2025 08:00AM PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease
Aug 27, 2025 08:00AM PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx(TM)), Aligned with FDA's CNPV National Priority Initiative
Aug 14, 2025 08:02AM PharmaTher receives FDA approval for ketamine product KETARx
Aug 14, 2025 08:00AM PharmaTher Founder and CEO Issues Letter to Shareholders Following the FDA Approval of Ketamine (KETARx(TM))
Aug 11, 2025 09:51AM PharmaTher receives FDA approval for ketamine product KETARx
Aug 11, 2025 09:49AM PharmaTher Announces FDA Approval of Ketamine (KETARx(TM))
Mar 3, 2025 08:00AM PharmaTher Provides Complete Response Amendment for US FDA New Drug Application for Ketamine
Oct 31, 2024 08:58AM PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases
Sep 19, 2024 08:00AM PharmaDrug's Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
Aug 28, 2024 08:00AM PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
Aug 21, 2024 09:52AM PharmaDrug's Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) Proteins
Aug 19, 2024 08:00AM PharmaDrug's Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated Cepharanthine